

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Friday, June 01, 2007

| Hide? | <u>Set</u> <u>Name</u> | <u>Query</u> | <u>Hit</u> <u>Count</u> |
|--------------------------|---------------------------|---|----------------------------|
| | | <i>DB=PGPB,USPT; PLUR=YES; OP=ADJ</i> | |
| <input type="checkbox"/> | L6 | 15 and (@AD<20020927 or @RLAD<20020927 or @PRAD<20020927) | 7 |
| <input type="checkbox"/> | L5 | L4 and (farnesyl or ras) | 12 |
| <input type="checkbox"/> | L4 | L2 and nasophar\$ | 37 |
| <input type="checkbox"/> | L3 | L2 and nasopharygneal | 0 |
| <input type="checkbox"/> | L2 | 514/220.icls. or 514/220.ccls. or 514/249.icls. or 514/249.ccls. or 514/250.icls. or 514/250.ccls. | 3964 |
| <input type="checkbox"/> | L1 | 20060293358.did. | 1 |

END OF SEARCH HISTORY

FILE 'REGISTRY' ENTERED AT 15:34:50 ON 01 JUN 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 2 S L3
L5 175 S L3 SSS FULL

FILE 'STNGUIDE' ENTERED AT 15:49:01 ON 01 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:51:31 ON 01 JUN 2007

L6 42 S L5
L7 3929 S NASOPHARYNGEAL
L8 922 S (FARNESYL TRANSFERASE)
L9 1 S L6 AND L7
L10 0 S L6 AND L8
L11 1 S L6 AND L9

FILE 'STNGUIDE' ENTERED AT 15:51:37 ON 01 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:52:06 ON 01 JUN 2007

L12 20008 S ANTHRACYCLLINE OR DOXORUBICIN OR DAUNORUBICIN OR EPIRUBACIN O
L13 0 S L6 AND L12

FILE 'STNGUIDE' ENTERED AT 15:52:09 ON 01 JUN 2007

FILE 'HCAPLUS' ENTERED AT 15:53:36 ON 01 JUN 2007

L14 24460 S ANTHRACYCLINE OR DOXORUBICIN OR DAUNORUBICIN OR EPIRUBICIN OR
L15 0 S L6 AND L12
L16 746 S (FARNESYL(W)TRANSFERASE) (2A) INHIB?
L17 2 S L7 AND L16

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 15:34:50 ON 01 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAY 2007 HIGHEST RN 936320-32-0

DICTIONARY FILE UPDATES: 31 MAY 2007 HIGHEST RN 936320-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10529431generic3.str



ring nodes :

1 2 3 4 5 6 7 8 9 10

ring bonds :

1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10

exact/norm bonds :

1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:35:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5431 TO ITERATE

36.8% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 104201 TO 113039

PROJECTED ANSWERS: 2926 TO 4568

L2 50 SEA SSS SAM L1


=> d l2 scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 8H-[1,4]Diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine,
9,10,11,12-tetrahydro-3-(phenylmethoxy)-9-[1-(phenylmethyl)-4-piperidinyl]-
(9CI)

MF C33 H36 N6 O

CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, N-[3-[(11S)-6-amino-1,2,3,4,8,9,10,11-octahydro-9-(methylsulfonyl)pyrazino[1',2':1,2]imidazo[4,5-c]quinolin-11-yl]propyl]-(9CI)
 MF C24 H30 N6 O3 S
 CI COM

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 8H-[1,4]Diazepino[1',2':1,2]imidazo[4,5-c]quinoline-9(10H)-carboxylic acid, 6-amino-11,12-dihydro-11-hydroxy-, ethyl ester, trifluoroacetate (salt) (9CI)
 MF C17 H19 N5 O3 . x C2 H F3 O2
 CM 1



CM 2




L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2(1H)-Phthalazineacetamide, 4-methyl-1-oxo-N-[1,2,3,4-tetrahydro-2-
 [(tetrahydro-2-furanyl)methyl]pyrazino[1,2-a]benzimidazol-8-yl]-
 MF C26 H28 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
 6-[(acetyloxy)[5,6,7,8-tetrahydro-7-(phenylmethyl)imidazo[1,2-a]pyrazin-2-
 yl)methyl]-6-bromo-7-oxo-, (4-nitrophenyl)methyl ester, (5R)-
 MF C29 H26 Br N5 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

0.66

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:35:29 ON 01 JUN 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 15:47:36 ON 01 JUN 2007

FILE 'REGISTRY' ENTERED AT 15:47:36 ON 01 JUN 2007

COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION


FULL ESTIMATED COST

0.45

0.66

=>

Uploading C:\Program Files\Stnexp\Queries\10529431limited.str



chain nodes :

20 21 22 23 25 26 34 35 36 41 44 45 46

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 27 28 30 31 32 33

chain bonds :

3-34 4-44 9-45 10-46 20-21 20-23 21-22 22-25 23-26 34-35 35-36 36-41

ring bonds :

1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10 13-14 13-17 14-15 15-16
16-17 27-28 27-33 28-30 30-31 31-32 32-33

exact/norm bonds :

1-2 1-7 2-3 3-4 3-34 4-5 4-44 5-6 5-8 6-7 6-10 8-9 9-10 9-45 10-46
13-14 13-17 14-15 15-16 16-17 20-21 20-23 21-22 22-25 23-26 27-28 27-33
28-30 30-31
31-32 32-33 34-35 35-36 36-41

G1:C,N

G2:C,H

G3:O,S,N,C

G4:N, [*1], [*2], [*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 20:CLASS 21:CLASS 22:CLASS 23:CLASS
25:CLASS 26:CLASS
27:CLASS 28:Atom 30:Atom 31:Atom 32:CLASS 33:CLASS 34:CLASS 35:Atom 36:Atom
41:CLASS
44:CLASS 45:CLASS 46:CLASS

L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 15:48:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5431 TO ITERATE

36.8% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 104201 TO 113039
PROJECTED ANSWERS: 2 TO 247


L4 2 SEA SSS SAM L3

=> d l4 scan


L4 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H20 N3 O2 S . F6 P

CM 1

Absolute stereochemistry. Rotation (+).



CM 2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,
6-[(acetyloxy)[5,6,7,8-tetrahydro-7-(phenylmethyl)imidazo[1,2-a]pyrazin-2-yl)methyl]-6-bromo-7-oxo-, (4-nitrophenyl)methyl ester, (5R)-

MF C29 H26 Br N5 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> 0

0 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 sss full
FULL SEARCH INITIATED 15:48:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 109146 TO ITERATE

100.0% PROCESSED 109146 ITERATIONS 175 ANSWERS
SEARCH TIME: 00.00.02

L5 175 SEA SSS FUL L3

| => file stnguide | SINCE FILE | TOTAL |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 173.00 | 173.21 |

FILE 'STNGUIDE' ENTERED AT 15:49:01 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2007 (20070525/UP).

| => file hcaplus | SINCE FILE | TOTAL |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.24 | 173.45 |

FILE 'HCAPLUS' ENTERED AT 15:51:31 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 31 May 2007 (20070531/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5

L6 42 L5

=> s nasopharyngeal

L7 3929 NASOPHARYNGEAL

=> s (farnesyl transferase)

| | |
|----|----------------------------|
| | 5410 FARNESYL |
| | 55668 TRANSFERASE |
| L8 | 922 (FARNESYL TRANSFERASE) |

(FARNESYL (W) TRANSFERASE)

=> s anthracycline or doxorubicin or daunorubicin or epirubicin or idarubicin or amrubicin)

UNMATCHED RIGHT PARENTHESIS 'AMRUBICIN)'

The number of right parentheses in a query must be equal to the number of left parentheses.

=> s l6 and l7

L9 1 L6 AND L7

=> s l6 and l8

L10 0 L6 AND L8

=> s l6 and l9

L11 1 L6 AND L9

=> file stnguide

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 2.60 | 176.05 |

FILE 'STNGUIDE' ENTERED AT 15:51:37 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2007 (20070525/UP).

=> file hcaplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.06 | 176.11 |

FILE 'HCAPLUS' ENTERED AT 15:52:06 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 31 May 2007 (20070531/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s anthracycline or doxorubicin or daunorubicin or epirubicin or idarubicin or amrubicin

```
      0 ANTHRACYCLLINE
16586 DOXORUBICIN
      4961 DAUNORUBICIN
      0 EPIRUBACIN
1486 IDARUBICIN
      125 AMRUBICIN
L12      20008 ANTHRACYCLLINE OR DOXORUBICIN OR DAUNORUBICIN OR EPIRUBACIN OR
      IDARUBICIN OR AMRUBICIN
```

=> s l6 and l12

L13 0 L6 AND L12

=> file stnguide

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 2.60 | 178.71 |

FILE 'STNGUIDE' ENTERED AT 15:52:09 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2007 (20070525/UP).

=> file hcaplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.12 | 178.83 |

FILE 'HCAPLUS' ENTERED AT 15:53:36 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 31 May 2007 (20070531/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s anthracycline or doxorubicin or daunorubicin or epirubicin or idarubicin or amrubicin

```
      5874 ANTHRACYCLINE
16586 DOXORUBICIN
```



4961 DAUNORUBICIN
 2557 EPIRUBICIN
 1486 IDARUBICIN
 125 AMRUBICIN
 L14 24460 ANTHRACYCLINE OR DOXORUBICIN OR DAUNORUBICIN OR EPIRUBICIN OR
 IDARUBICIN OR AMRUBICIN

=> s l6 and l12

L15 0 L6 AND L12

=> d l9 ti abs bib

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds as
 tyrosine kinase inhibitors
 GI



AB The title compds. I [a, b = 0 or 1; m = 0-2; R1 = halo, aryl, heterocyclyl, etc.; R2, R3 = H, OH, alkoxy, etc.; R2 and R3 combined = :O or :N(ORa); R4, R6, R7 = H, halo, alkyl, etc.; R5 = H, alkyl, alkenyl, etc.; Ra = H, alkyl, aryl, etc.], useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET, were prepared E.g., a multi-step synthesis of II, starting from 4-bromobenzaldehyde and Me 5-chloro-2-methylnicotinate, was given. Exemplified compds. I were tested and found to have MET inhibitory activity. Representative compds. I showed IC50 ≤50 μM against c-MET kinase (in vitro assay). The invention also relates to compns. which comprise compds. I, and methods of using them to treat cancer in mammals.

AN 2006:1358155 HCAPLUS <<LOGINID::20070601>>

DN 146:100574

TI Preparation of 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds as tyrosine kinase inhibitors

IN Dinsmore, Christopher J.; Gabarda Ortega, Ana Esther; Guerin, David J.; Jewell, James P.; Katz, Jason D.; Lim, Jongwon; Machacek, Michelle R.; Otte, Ryan D.; Young, Jonathan R.

PA USA

SO U.S. Pat. Appl. Publ., 128pp., which

CODEN: USXXCO

DT Patent
LA English
FAN.CNT 2



| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2006293358 | A1 | 20061228 | US 2006-473273 | 20060622 |
| | WO 2007002254 | A2 | 20070104 | WO 2006-US24247 | 20060622 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2005-693229P | P | 20050623 | | |
| | US 2005-729061P | P | 20051021 | | |
| OS | MARPAT 146:100574 | | | | |

=> d l11 ti abs bib

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds as tyrosine kinase inhibitors

GI



AB The title compds. I [a, b = 0 or 1; m = 0-2; R1 = halo, aryl, heterocyclyl, etc.; R2, R3 = H, OH, alkoxy, etc.; R2 and R3 combined = :O or :N(ORa); R4, R6, R7 = H, halo, alkyl, etc.; R5 = H, alkyl, alkenyl, etc.; Ra = H, alkyl, aryl, etc.], useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET, were prepared E.g., a multi-step synthesis of II, starting from 4-bromobenzaldehyde and Me 5-chloro-2-methylnicotinate, was given. Exemplified compds. I were tested and found to have MET inhibitory activity. Representative compds. I

showed IC50 ≤50 μM against c-MET kinase (in vitro assay). The invention also relates to compns. which comprise compds. I, and methods of using them to treat cancer in mammals.

AN 2006:1358155 HCAPLUS <<LOGINID::20070601>>

DN 146:100574

TI Preparation of 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds as tyrosine kinase inhibitors

IN Dinsmore, Christopher J.; Gabarda Ortega, Ana Esther; Guerin, David J.; Jewell, James P.; Katz, Jason D.; Lim, Jongwon; Machacek, Michelle R.; Otte, Ryan D.; Young, Jonathan R.

PA USA

SO U.S. Pat. Appl. Publ., 128pp., which

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | --- | ----- | ----- | ----- |
| PI | US 2006293358 | A1 | 20061228 | US 2006-473273 | 20060622 |
| | WO 2007002254 | A2 | 20070104 | WO 2006-US24247 | 20060622 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2005-693229P | P | 20050623 | | |
| | US 2005-729061P | P | 20051021 | | |
| OS | MARPAT 146:100574 | | | | |

=> s (farnesyl(w)transferase) (2a) inhib?

5410 FARNESYL
55668 TRANSFERASE
1933628 INHIB?

L16 746 (FARNESYL(W)TRANSFERASE) (2A) INHIB?

=> s 17 and l16

L17 2 L7 AND L16

=> file stnguide

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST | 8.26 | 187.09 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -1.56 | -1.56 |

FILE 'STNGUIDE' ENTERED AT 15:53:43 ON 01 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE


FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 25, 2007 (20070525/UP).

=> d 117 1-2 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Compositions containing farnesyl transferase
inhibitors for the treatment of nasopharyngeal carcinoma
GI



AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 HCAPLUS <<LOGINID::20070601>>

DN 140:315043

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel

PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2004028541 | A2 | 20040408 | WO 2003-IB4922 | 20030929 |
| | WO 2004028541 | A3 | 20040701 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2003274565 | A1 | 20040419 | AU 2003-274565 | 20030929 |
| | EP 1542691 | A2 | 20050622 | EP 2003-758540 | 20030929 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| | JP 2006500421 | T | 20060105 | JP 2004-539385 | 20030929 |

| | | | | | |
|------|-------------------|----|----------|----------------|----------|
| | US 2006166907 | A1 | 20060727 | US 2005-529431 | 20050325 |
| PRAI | US 2002-414103P | P | 20020927 | | |
| | WO 2003-IB4922 | W | 20030929 | | |
| OS | MARPAT 140:315043 | | | | |

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor

AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 µM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 µM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.

AN 2003:28618 HCAPLUS <<LOGINID::20070601>>

DN 139:46523

TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor

AU Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak, Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jlidi, Rachid; Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.; Busson, Pierre

CS UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.

SO Biochemical Pharmacology (2003), 65(3), 423-433

CODEN: BCPCA6; ISSN: 0006-2952

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT